Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

@article{Deisenhammer2017OcrelizumabIP,
  title={Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.},
  author={F. Deisenhammer and M. Auer and H. Hegen},
  journal={The New England journal of medicine},
  year={2017},
  volume={376 17},
  pages={
          1693-4
        }
}
n engl j med 376;17 nejm.org April 27, 2017 1692 tients from the United States and Canada and 66 of 70 patients from Russia), canrenone concentrations were undetectable in a higher percentage of participants from Russia than from the United States and Canada (30% vs. 3%, P<0.001) (Fig. 1B). In an analysis of all the participants who reported taking the assigned doses of spironolactone, a significant correlation between the doses of spironolactone that the participants reported taking and… Expand

References

SHOWING 1-10 OF 11 REFERENCES
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Interferon β-1a in MS
...
1
2
...